文献速递免疫规划

经肌内电穿孔递送的DNA疫苗所编码的Pfs48/45与Pfs25的免疫原性及降低疟疾传播效力

Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
PubMed 文献 · Vaccine · 2016-11-29

本研究比较了编码全长Pfs48/45的DNA质粒(野生型、密码子优化型及两种去N-糖基化突变型)加或不加肌内电穿孔(EP)的免疫效果,并评估了DNA初免后重组蛋白加强及与Pfs25 DNA联合免疫的策略。结果显示EP显著增强SYN Pfs48/45 DNA疫苗诱导的抗体滴度和传播阻断活性,SYN Pfs48/45功能免疫原性优于MUT1或MUT2,重组蛋白加强可显著提升所有四种DNA疫苗的抗体应答和传播减少能力,SYN Pfs48/45与SYN Pfs25联合DNA免疫支持靶向不同生活史阶段抗原联合使用的可能性。

要点

  • 肌内电穿孔(EP)显著增强SYN Pfs48/45 DNA疫苗诱导的抗体滴度和传播阻断活性。
  • SYN Pfs48/45(N-糖基化位点完整)的功能免疫原性优于MUT1或MUT2(所有N-糖基化位点突变)。
  • DNA初免后重组Pfs48/45蛋白加强可显著提升所有四种DNA疫苗的抗体应答和传播减少能力。

核心结论

  • 全长Pfs48/45 DNA质粒能诱导显著的传播减少免疫应答,EP可增强SYN Pfs48/45 DNA疫苗的抗体滴度和传播阻断活性。
  • SYN Pfs48/45的功能免疫原性优于MUT1或MUT2,重组蛋白加强可显著提升所有四种DNA疫苗的抗体应答和传播减少能力。
  • SYN Pfs48/45与SYN Pfs25联合DNA免疫支持在蚊传播阶段联合靶向不同生活史阶段抗原的可能性。

研究设计与样本

  • 研究比较了编码Pfs48/45的DNA质粒(基于野生型、密码子优化型、密码子优化并突变以防止N-连接糖基化的MUT1和MUT2)加或不加肌内电穿孔的免疫效果。
  • 评估了DNA初免后重组Pfs48/45蛋白加强以及SYN Pfs48/45与SYN Pfs25联合DNA免疫的策略。
  • 采用蚊膜饲喂实验评估传播阻断活性。

主要发现

  • EP显著增强SYN Pfs48/45 DNA疫苗免疫所诱导的抗体滴度和传播阻断活性。
  • 蚊膜饲喂实验显示SYN Pfs48/45(N-糖基化位点完整)的功能免疫原性优于MUT1或MUT2 Pfs48/45 DNA质粒(所有N-糖基化位点突变)。
  • 用重组Pfs48/45蛋白加强后,所有四种DNA疫苗的抗体应答均显著增强,传播减少能力改善。
  • SYN Pfs48/45与SYN Pfs25联合DNA免疫支持联合靶向不同生活史阶段抗原的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pfs48/45 and Pfs25 are leading candidates for the development of Plasmodium falciparum transmission blocking vaccines (TBV). Expression of Pfs48/45 in the erythrocytic sexual stages and presentation to the immune system during infection in the human host also makes it ideal for natural boosting. However, it has been challenging to produce a fully folded, functionally active Pfs48/45, using various protein expression platforms. In this study, we demonstrate that full-length Pfs48/45 encoded by DNA plasmids is able to induce significant transmission reducing immune responses. DNA plasmids encoding Pfs48/45 based on native (WT), codon optimized (SYN), or codon optimized and mutated (MUT1 and MUT2), to prevent any asparagine (N)-linked glycosylation were compared with or without intramuscular electroporation (EP). EP significantly enhanced antibody titers and transmission blocking activity elicited by immunization with SYN Pfs48/45 DNA vaccine. Mosquito membrane feeding assays also revealed improved functional immunogenicity of SYN Pfs48/45 (N-glycosylation sites intact) as compared to MUT1 or MUT2 Pfs48/45 DNA plasmids (all N-glycosylation sites mutated). Boosting with recombinant Pfs48/45 protein after immunization with each of the different DNA vaccines resulted in significant boosting of antibody response and improved transmission reducing capabilities of all four DNA vaccines. Finally, immunization with a combination of DNA plasmids (SYN Pfs48/45 and SYN Pfs25) also provides support for the possibility of combining antigens targeting different life cycle stages in the parasite during transmission through mosquitoes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Datta D, Bansal GP, Gerloff DL, et al. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine. 2016. PMID: 27912985. doi:10.1016/j.vaccine.2016.11.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。